Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Waste Manag ; 157: 301-311, 2023 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-36584494

RESUMO

Municipal solid waste (MSW) production in the world has increased by 60 % in recent years. Incineration of MSW reduces their volume in conjunction with energy recovery. Incineration produces two residues, namely bottom ash (BA) and fly ash (FA), with high concentration of heavy metals and organic pollutants, especially for FA, making them an environmental concern. Vitrification is a costly, highly safe high temperature treatment, ensuring encapsulation of heavy metals. FA vitrification requires a source of silica to be able to get vitrified. In this study, we have proposed valorizing treated (vitrified) FA through the production of porous glass-ceramics, subsequently to MSWI. The entire process, from incineration to glass-ceramics production, was evaluated for several scenarios by Life Cycle Assessment (LCA) using Sima Pro 9.0. Three main scenarios were analysed; each one considering a different silica source: bottom ash (BA), glass cullet (G) and silica sand (S), and for each scenario, three thermal recovery subscenarios were assumed: no thermal recovery used to heat FA prior to vitrification (N), heating FA prior to vitrification using incineration gases thermal recovery (T) and methane-combustion-aided thermal recovery, which exploits methane combustion to further increase the gases temperature (M). Results proved that vitrification was a technically feasible and environmentally-energetically sustainable technology. The result indicates that the most eco-sustainable scenario was using bottom ashes as a silica source together with methane-combustion-aided recovery: 0.467 kgCO2,eq, 5.83 × 10-8 carcinogenic-CTUh and 9.26 MJ required per kg of glass-ceramics produced.


Assuntos
Metais Pesados , Eliminação de Resíduos , Animais , Cinza de Carvão/química , Metano/análise , Dióxido de Silício , Porosidade , Incineração/métodos , Metais Pesados/análise , Resíduos Sólidos/análise , Gases/análise , Cerâmica , Estágios do Ciclo de Vida , Carbono , Material Particulado
2.
Commun Biol ; 4(1): 1249, 2021 11 02.
Artigo em Inglês | MEDLINE | ID: mdl-34728774

RESUMO

Differentially DNA methylated regions (DMRs) inform on the role of epigenetic changes in cancer. We present Rocker-meth, a new computational method exploiting a heterogeneous hidden Markov model to detect DMRs across multiple experimental platforms. Through an extensive comparative study, we first demonstrate Rocker-meth excellent performance on synthetic data. Its application to more than 6,000 methylation profiles across 14 tumor types provides a comprehensive catalog of tumor type-specific and shared DMRs, and agnostically identifies cancer-related partially methylated domains (PMD). In depth integrative analysis including orthogonal omics shows the enhanced ability of Rocker-meth in recapitulating known associations, further uncovering the pan-cancer relationship between DNA hypermethylation and transcription factor deregulation depending on the baseline chromatin state. Finally, we demonstrate the utility of the catalog for the study of colorectal cancer single-cell DNA-methylation data.


Assuntos
Biologia Computacional/métodos , Metilação de DNA , Epigênese Genética , Neoplasias/genética , Humanos , Cadeias de Markov
3.
Artigo em Inglês | MEDLINE | ID: mdl-33015524

RESUMO

PURPOSE: The tumor microenvironment is complex, comprising heterogeneous cellular populations. As molecular profiles are frequently generated using bulk tissue sections, they represent an admixture of multiple cell types (including immune, stromal, and cancer cells) interacting with each other. Therefore, these molecular profiles are confounded by signals emanating from many cell types. Accurate assessment of residual cancer cell fraction is crucial for parameterization and interpretation of genomic analyses, as well as for accurately interpreting the clinical properties of the tumor. MATERIALS AND METHODS: To benchmark cancer cell fraction estimation methods, 10 estimators were applied to a clinical cohort of 333 patients with prostate cancer. These methods include gold-standard multiobserver pathology estimates, as well as estimates inferred from genome, epigenome, and transcriptome data. In addition, two methods based on genomic and transcriptomic profiles were used to quantify tumor purity in 4,497 tumors across 12 cancer types. Bulk mRNA and microRNA profiles were subject to in silico deconvolution to estimate cancer cell-specific mRNA and microRNA profiles. RESULTS: We present a systematic comparison of 10 tumor purity estimation methods on a cohort of 333 prostate tumors. We quantify variation among purity estimation methods and demonstrate how this influences interpretation of clinico-genomic analyses. Our data show poor concordance between pathologic and molecular purity estimates, necessitating caution when interpreting molecular results. Limited concordance between DNA- and mRNA-derived purity estimates remained a general pan-cancer phenomenon when tested in an additional 4,497 tumors spanning 12 cancer types. CONCLUSION: The choice of tumor purity estimation method may have a profound impact on the interpretation of genomic assays. Taken together, these data highlight the need for improved assessment of tumor purity and quantitation of its influences on the molecular hallmarks of cancers.

4.
Bioresour Technol ; 289: 121631, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31220764

RESUMO

Non-sterile lactic acid (LA) fermentation of highly viscous food waste was demonstrated in batch and continuous flow fermentations. With Streptococcus sp., an indigenous consortium, and/or applied glucoamylase, food waste was fermented without addition of external carbon or nitrogen sources. Experimental results were used for economic and energy evaluations under consideration of different catchment area sizes from 50,000 to 1,000,000 inhabitants. During batch mode, addition of glucoamylase resulted in a titer (after 24 h), yield, and productivity of 50 g L-1, 63%, and 2.93 g L-1h-1, respectively. While titer and yield were enhanced, productivity was lower during continuous operation and 69 g L-1, 86%, and 1.27 g L-1h-1 were obtained at a dilution rate of 0.44 d-1 when glucoamylase was added. Both batch and continuous flow fermentations were found economically profitable with food waste from 200,000 or more inhabitants.


Assuntos
Alimentos , Ácido Láctico , Reatores Biológicos , Fermentação , Glucana 1,4-alfa-Glucosidase , Nitrogênio
5.
Appl Immunohistochem Mol Morphol ; 22(2): 136-41, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24517914

RESUMO

The ERG rearrangement is identified in approximately 50% of prostate cancer screened cohorts and is known to be highly specific. This genetic aberration, most commonly leading to the TMPRSS2-ERG fusion, but also SLC45A3-ERG or NDRG1-ERG fusions, all leading to an overexpression of a truncated ERG protein. Most studies have applied in situ hybridization (FISH) methods or mRNA-based assays to investigate the ERG status. Recently, studies showed that ERG protein levels assessed by ERG antibodies can be used as a surrogate marker for ERG rearrangement. In the current study, we investigate ERG status on a series of diagnostic biopsies using DNA-based, mRNA-based, and protein-based assays. We formally compared 3 assay results (ie, FISH, fusion mRNA, and immunohistochemistry) to identify which method could be most appropriate to use when having limited amount of tissue. ERG rearrangement was found in 56% of the cases. Comparing ERG rearrangement status by FISH with ERG overexpression and TMPRSS2-ERG fusion transcript we found 95.1% (154/162, Fisher exact test 9.50E-36) and 85.2% (138/162, Fisher exact test 7.26E-22) concordance, respectively. We show that the ERG antibody highly correlates with the ERG rearrangement with high sensitivity and specificity. We also identified the most common TMPRSS2-ERG isoform in the majority of ERG rearranged cases. These results provide compelling evidence that the ERG antibody can be used to further investigate the role of ERG in prostate cancer.


Assuntos
Carcinoma/diagnóstico , Imuno-Histoquímica/métodos , Hibridização in Situ Fluorescente/métodos , Neoplasias da Próstata/diagnóstico , Transativadores/metabolismo , Idoso , Anticorpos Monoclonais/metabolismo , Biópsia , Carcinoma/genética , Estudos de Coortes , DNA/análise , Estudos de Viabilidade , Rearranjo Gênico , Humanos , Masculino , Proteínas de Fusão Oncogênica/genética , Neoplasias da Próstata/genética , RNA Mensageiro/análise , Sensibilidade e Especificidade , Suécia , Transativadores/genética , Regulador Transcricional ERG
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA